BCR-ABL-1 Quantitative
RT-PCR Kit - Major
BCR-ABL Quantitative RT-PCR kit is a in-vitro multiplex, one-step, TaqMan probe-based quantitative assay for the specific detection and quantitation of Major transcripts in the RNA/cDNA (template) extracted from EDTA whole blood or bone marrow aspirate of humans with Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) symptoms. The kit can detect the Deep Molecular Response up to 5 Log reduction.
SKU
-
100 Rxns : NDXIVD002
-
50 Rxns : NDXIVD002_01
-
20 Rxns : NDXIVD002_02
CDSCO
Approved
Features & Benefits:
-
IS quantitative, one-step RT-PCR for quantifying the IS ratios of BCR-ABL Major (M-BCR) p210 transcript in CML patient samples.
-
Evaluates the molecular response up to 5 log reduction. The reporting is based on European Treatment and Outcome Study (EUTOS) guidelines and European Leukemia Net (ELN) recommendations
-
The quantitation standards provided are with known copy numbers and are calibrated against WHO 1st International Genetic Reference Panel for the quantitation of BCR-ABL1 translocation (09/138) for assigning IS values to a measured level of BCR ABL/ABL %.
-
The kit supports reverse transcription. No additional cDNA steps are required.
-
The minor BCR-ABL1 and micro BCR-ABL1 are reported in NCN%.
-
High-Quality Reverse transcriptase and Taq HS in the Mastermix show Increased Inhibitor Tolerance, Thermostability, and Reproducibility.
-
PCR run time: 90 Minutes
-
Works with RNA extracted from Whole Blood EDTA and Bone Marrow Aspirates
Storage & Precautions
-
Recommended Storage: -20°C
-
For Professional Use only.
-
Read user manual
Clinical Relevance
The BCR-ABL fusion gene, arising from the reciprocal translocation t(9;22)(q34;q11) known as the Philadelphia chromosome, encodes a constitutively active tyrosine kinase that is central to the pathogenesis of Chronic Myeloid Leukaemia (CML). Quantitative detection of the major BCR-ABL transcript (p210; e13a2/e14a2) is clinically relevant for establishing a baseline molecular disease burden at diagnosis and for longitudinal monitoring of treatment response during tyrosine kinase inhibitor therapy. Serial measurement of BCR-ABL transcript levels enables assessment of molecular response milestones, detection of minimal residual disease, and early identification of loss of response or molecular relapse, thereby supporting timely therapeutic decision-making and long-term disease management in patients with Philadelphia chromosome positive CML
